The tweet was deleted by the author.
But we saved everything 🙂.
Protagonist Therapeutics received U.S. FDA approval for ICOTYDE (icotrokinra) as a new oral peptide therapy for plaque psoriasis.
ICOTYDE is the first targeted oral peptide option approved for first-line systemic treatment of this chronic skin condition. The company credited its science platform, research team, Johnson & Johnson, clinical investigators, and patients for supporting the breakthrough. The approval marks a significant advance in expanding treatment options for people living with plaque psoriasis.
ICOTYDE’s approval further highlights the progress driven by Protagonist Therapeutics’ pioneering peptide technology, a foundation the company notably detailed in its previous showcase of its innovative platform. This development underscores the expanding role of peptide-based therapies in addressing complex medical needs.